|
|
Last Modified: 3/13/2007  First Published: 4/21/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CTRG-HC06/21/05 NCI-7237, 7237, NCT00321594
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
PXD101-CLN-8 PXD101-040-EU, NCT00421889
|
|
|
|
|
|
|
|
Last Modified: 1/21/2008  First Published: 3/3/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
PMH-PHL-041 7267, NCI-7267, NCT00301756
|
|
|
|
|
|
|
|
Last Modified: 9/19/2008  First Published: 3/13/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
SWOG-S0520 S0520, NCT00303953
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
PXD101-CLN-6 NCT00274651
|
|
|
|
|
|
|
|
Last Modified: 4/2/2008  First Published: 7/23/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MAYO-MC0581 7258, NCI-7258, NCT00357162
|
|
|
|
|
|
|
|
Last Modified: 8/14/2008  First Published: 12/24/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
NCI
|
|
|
|
NCI-08-C-0033 08-C-0033, 8174, NCT00589290, NCI-P07249
|
|
|
|
|
|
|
|
Last Modified: 10/24/2007  First Published: 6/23/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
UCHSC-05-0705 7281, NCI-7281, UCHSC-COMIRB-05-0705, NCT00348985
|
|
|
|
|
|
|
|
Last Modified: 4/17/2008  First Published: 5/23/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CCC-PHI-53 7251, NCI-7251, NCT00334789
|
|
|
|
|
|
|
|
Last Modified: 5/22/2008  First Published: 7/7/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
UCCRC-NCI-7285 7285, NCI-7285, NCT00351975
|
|
|
|